Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Clinical Study of KHK4827

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had stable moderate to severe plaque psoriasis for at least 6 months.~* Subject has received at least one previous phototherapy or systemic psoriasis therapy or has been a candidate to receive phototherapy or systemic psoriasis therapy in the opinion of the investigator.~* Subject has involved BSA ≥ 10% and PASI ≥ 12 at screening and at baseline.~Exclusion Criteria:~* Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced, or medication-exacerbated psoriasis.~* Evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of investigational product on psoriasis.~* Subject has any active Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher infection~* Subject has a significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol.~* Subject has used the following therapies within 14 days of the first dose: topical calcineurin inhibitors including tacrolimus~  , topical vitamin A, activated form D3 or activated form D3 analogue preparations, weak through strong topical steroids (excluding application on the scalp, axillae, and groin)~* Subject has used the following therapies within 28 days of the first dose: any other systemic psoriasis therapy (eg, vitamin A, calcineurin inhibitors, methotrexates, steroids), UVA therapy (with or without psoralen), very strong or strongest topical steroid, tar therapy~* Subject has used the following therapies within 3 months of the first dose: adalimumab, etanercept, infliximab, or live vaccines~* Subject has used ustekinumab within 6 months of the first dose~* Subject has previously used an anti-interleukin-17 biologic therapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- KHK4827 70mg SC (Type: EXPERIMENTAL): None
- KHK4827 140mg SC (Type: EXPERIMENTAL): None
- KHK4827 210mg SC (Type: EXPERIMENTAL): None
- Placebo SC (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).